Phospholipids

Subscribe to Selected New Research on Phospholipids

3567 relevant articles (59 outcomes, 289 trials/studies) found for this Bio-Agent

Description: Lipids containing one or more phosphate groups, particularly those derived from either glycerol (phosphoglycerides see GLYCEROPHOSPHOLIPIDS) or sphingosine (SPHINGOLIPIDS). They are polar lipids that are of great importance for the structure and function of cell membranes and are the most abundant of membrane lipids, although not stored in large amounts in the system.

Also Known As:

Phosphatides

Relationship Network

Bio-Agent Context: Research Results

Lipids: 13939

Phospholipids: 3567

contrast agent BR1: 119

poractant alfa: 93

bovine surfactant preparation SF-RI 1: 19

lipopeptidophosphoglycan: 4

pediatric fat emulsion 4501: 1

peritoneal dialysate-depressor-I: 1

(4,5-3H)-dihydrosphingosine-1-phosphate

1,2-dipalmitoyl-alpha-phosphatidyl-3-(4-methoxyphenyl)umbelliferone

1,2-O-docosylidene-sn-glycero-3-phospho(1'-ribosyl)ethanolamine

1-(12-methyltetradecanoyl)-3-phosphoglyceroglycerol

1-(2'-thio-1'-hydroxyethyl)-2-(ethylphosphatidyl)isoindole

1-nitrophenyl-octylphosphonate-2-tridecylcarbamoyl-3-ethanesulfonylamino-3-deoxyglycerol

1-O-cis-alk-1'-enyl-2-lyso-sn-glycero-3-phosphate

1-O-hexadecyl-2-O-perylenedodecyl-sn-glycero-3-phosphonic acid-(n-hexyl)-4-nitrophenyl ester

1-O-octyl-2-O-pyrenebutyl-sn-glycero-3-phosphonic acid-(n-hexyl)-4-nitrophenyl ester

1-thio-octyl-2-heptylphosphonyl-1-deoxyglycero-3-phosphoglycol

2'-(trimethylammonio)-ethyl-4-(hexadecylthio)-3-methoxybutane phosphonate

2'-(trimethylammonio)ethyl 4-(hexadecyloxy)-(3)-3-methoxy-1-butenephosphonate

2'-(trimethylammonio)ethyl-4-(hexadecyloxy)-3-methoxybutane phosphonate

2-aminoethylphosphonolipid

2-N-palmitoylnorleucinol-1-phosphoglycol

3'-deoxythymidine diphosphate 1-myristoyl-2-(10-pyren-1-yl-decanoyl)glycerol

3'-deoxythymidine diphosphate dimyristoylglycerol

artificial lung expanding compound

bovine vitreous lipid factor

BR14 contrast agent

Concentrin

dehydroepiandrosterone phosphatide

di(triethyleneglycoltetradecylether) phosphate

dipetroselinoyl-PE

diphenyl (N-(benzyloxycarbonyl)amino)(4-amidinophenyl)methane phosphonate

diumycin

divaccenoyl-PE

dodecyl-2-aminohexanol-1-phosphoglycol

glucosylcaldarchaetidylglycerol

lysate brain depressor-I

MG14

N'-(1,2-dimyristoyl-sn-glycero-3-phosphoethyl)-N-(3-(3-trifluoromethyl)diazirine)phenylthiourea

O-perylenebutylmethylphosphonic acid-4-nitrophenyl ester

octadecyl-(N,N-dimethylpiperidino-4-yl)-phosphate

PGP-Me

phosphatidylethylene glycol

silimat

syringomyelin

tocopheryl-6-O-phosphorylethanolamine

Trypanosoma glycoinositolphospholipid

Membrane Lipids: 350

Phospholipids: 3567

contrast agent BR1: 119

poractant alfa: 93

Sphingomyelins: 22

bovine surfactant preparation SF-RI 1: 19

Glycerophosphates: 10

Lipofundin S: 8

lipopeptidophosphoglycan: 4

pediatric fat emulsion 4501: 1

peritoneal dialysate-depressor-I: 1

(4,5-3H)-dihydrosphingosine-1-phosphate

1,2-dipalmitoyl-alpha-phosphatidyl-3-(4-methoxyphenyl)umbelliferone

1,2-O-docosylidene-sn-glycero-3-phospho(1'-ribosyl)ethanolamine

1-(12-methyltetradecanoyl)-3-phosphoglyceroglycerol

1-(2'-thio-1'-hydroxyethyl)-2-(ethylphosphatidyl)isoindole

1-nitrophenyl-octylphosphonate-2-tridecylcarbamoyl-3-ethanesulfonylamino-3-deoxyglycerol

1-O-cis-alk-1'-enyl-2-lyso-sn-glycero-3-phosphate

1-O-hexadecyl-2-O-perylenedodecyl-sn-glycero-3-phosphonic acid-(n-hexyl)-4-nitrophenyl ester

1-O-octyl-2-O-pyrenebutyl-sn-glycero-3-phosphonic acid-(n-hexyl)-4-nitrophenyl ester

1-thio-octyl-2-heptylphosphonyl-1-deoxyglycero-3-phosphoglycol

2'-(trimethylammonio)-ethyl-4-(hexadecylthio)-3-methoxybutane phosphonate

2'-(trimethylammonio)ethyl 4-(hexadecyloxy)-(3)-3-methoxy-1-butenephosphonate

2'-(trimethylammonio)ethyl-4-(hexadecyloxy)-3-methoxybutane phosphonate

2-aminoethylphosphonolipid

2-N-palmitoylnorleucinol-1-phosphoglycol

3'-deoxythymidine diphosphate 1-myristoyl-2-(10-pyren-1-yl-decanoyl)glycerol

3'-deoxythymidine diphosphate dimyristoylglycerol

artificial lung expanding compound

bovine vitreous lipid factor

BR14 contrast agent

Concentrin

dehydroepiandrosterone phosphatide

di(triethyleneglycoltetradecylether) phosphate

dipetroselinoyl-PE

diphenyl (N-(benzyloxycarbonyl)amino)(4-amidinophenyl)methane phosphonate

diumycin

divaccenoyl-PE

dodecyl-2-aminohexanol-1-phosphoglycol

glucosylcaldarchaetidylglycerol

lysate brain depressor-I

MG14

N'-(1,2-dimyristoyl-sn-glycero-3-phosphoethyl)-N-(3-(3-trifluoromethyl)diazirine)phenylthiourea

O-perylenebutylmethylphosphonic acid-4-nitrophenyl ester

octadecyl-(N,N-dimethylpiperidino-4-yl)-phosphate

PGP-Me

phosphatidylethylene glycol

silimat

syringomyelin

tocopheryl-6-O-phosphorylethanolamine

Trypanosoma glycoinositolphospholipid

Experts

1.	Leitinger, Norbert: 9 articles (01/2008 - 01/2002)
2.	Schumpelick, Volker: 7 articles (01/2007 - 01/2002)
3.	Witztum, Joseph L: 6 articles (08/2008 - 01/2002)
4.	Thorpe, Philip E: 5 articles (09/2007 - 11/2002)
5.	Jansen, Marc: 5 articles (01/2007 - 01/2002)
6.	Bochkov, Valery N: 4 articles (01/2008 - 03/2005)
7.	Berliner, Judith A: 4 articles (10/2007 - 06/2004)
8.	Tsimikas, Sotirios: 4 articles (01/2007 - 09/2004)
9.	Treutner, Karl-Heinz: 4 articles (01/2007 - 01/2004)
10.	Jansen, Petra Lynen: 4 articles (01/2007 - 01/2004)

Related Diseases

1.	Neoplasms (Cancer) 12/15/2004 - "RESULTS: Both LDL and albumin were effective in delivering FA to tumor cells and modifying the composition of cell phospholipids. " 02/15/2005 - "In the present study, we tested the hypothesis that a monoclonal antibody directed against anionic phospholipids might exert antitumor effects by causing vascular damage in tumors. " 11/01/2002 - "In the present study, we determined whether anionic phospholipids become exposed on tumor vasculature. " 07/01/2009 - "Levels of membrane phospholipids of red blood cells reflected dietary changes and correlated with the levels observed in tumors. " 08/01/2008 - "The research on cultured cells by using NMR spectroscopy showed that the signal of various phospholipids and their metabolites such as PME increased significantly in cultured cancer cells. " Order ALL the reference details at left...
2.	Bipolar Disorder (Mania) 05/30/2001 - "Published literature comparing 31P MR brain spectra of bipolar patients to healthy controls was evaluated, focusing on phosphomonoester (PME)/phosphodiester (PDE) resonance areas because these metabolites are related to membrane phospholipids and membrane defects in bipolar disorder have been suggested. " 02/15/1999 - "Platelet membrane phospholipids in euthymic bipolar disorder patients: are they affected by lithium treatment?" 10/01/2005 - "CONCLUSIONS: The results, comparable to published findings following chronic administration of lithium and carbamazepine to rats, support the hypothesis that drugs are effective against mania in bipolar disorder act by downregulating incorporation and turnover of AA, but not of DHA, in brain phospholipids." 01/01/2008 - "Whereas antibipolar drug administration to rats reduces brain arachidonic acid turnover, excessive N-methyl-d-aspartate (NMDA) signaling is thought to contribute to bipolar disorder symptoms and may increase arachidonic acid turnover in rat brain phospholipids. " 09/01/2007 - "Chronic lamotrigine does not alter the turnover of arachidonic acid within brain phospholipids of the unanesthetized rat: implications for the treatment of bipolar disorder." Order ALL the reference details at left...
3.	Syndrome 04/01/1989 - "The authors have investigated the therapeutic efficacy of hypothalamic phospholipids in the menopausal syndrome. " 08/12/2003 - "An infrared reflection-absorption spectroscopy study of the secondary structure in (KL4)4K, a therapeutic agent for respiratory distress syndrome, in aqueous monolayers with phospholipids." 01/01/2000 - "SELECTION CRITERIA: Randomized controlled trials which compared the effect of prophylactic natural surfactant administration (surfactant obtained from human or bovine sources, either modified with additional phospholipids or not) administered to high risk preterm newborns at or shortly after birth in order to prevent respiratory distress syndrome, other complications of prematurity, and mortality. " 04/01/2009 - "Metabolic syndrome and serum fatty acid patterns in serum phospholipids in hypertriglyceridemic persons with human immunodeficiency virus." 12/01/1997 - "Our results provide the first insight that the lack of expression of procoagulant phospholipids and microparticle formation in Scott syndrome platelets is associated with a defect of intracellular signalling." Order ALL the reference details at left...
4.	Anoxia (Hypoxia) 09/01/1993 - "Finally, these studies suggested that alterations in phospholipids during hypoxia occurred to a greater extent in compartments of endothelial cells other than the plasma membranes and that the well-recognized tolerance of endothelial cells to hypoxia may be due, in part, to preservation of the integrity of their plasma membranes during exposure to acute and chronic hypoxia." 01/01/1993 - "Studies of the structural changes of erythrocytic phospholipids and their free-radical oxidation in health and intrauterine hypoxia in 61 parturients and their fetuses have shown that, despite a variety of causes of intrauterine hypoxia, the structural changes of fetal red cells are virtually the same and present as enlarged crystals and more marked crystallization of the phospholipid layer of the membrane. " 09/01/2006 - "Fatty acid composition of phospholipids of the cell nuclei from the rat brain after hypoxia at different periods of ontogeny." 03/01/2004 - "Previous hypobaric hypoxic hypoxia reduced the level of total phospholipids as well as PS at simultaneous increase of LPL. " 03/01/2004 - "Previous hypoxia altered the character of autolytic reorganizations of phospholipids. " Order ALL the reference details at left...
5.	Body Weight (Weight, Body) 01/01/2007 - "They received either phospholipids 3.0% or normal saline (NaCl 0.9%) (5 ml/kg body weight). " 08/01/2002 - "A significant increase in lung and liver phospholipids was observed after 21 and 28 days of AD (175 mg/kg body weight/day) treatment. " 02/29/2000 - "Control animals lost body weight in the same manner as the infected animals, but had elevated cholesterols and phospholipids with normal triglyceride concentrations. " 04/01/1999 - "Therefore, rats which received a lavage of 4x4 mL per animal (groups 4 to 6) or 7x8 mL per animal (groups 10-12) were treated intratracheally with surfactant doses of 12.5, 25, or 100 mg phospholipids (PL) per kg body weight (bw). " 09/01/1995 - "The exponential disappearance of PG and Sph from repetitive airway samples was utilized to calculate an apparent endogenous pool size, for the time before surfactant treatment, of about 20 mg phospholipids/kg body weight (n = 14). " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Cholesterol
2.	Lipids
3.	Nonesterified Fatty Acids (NEFA)
4.	Arachidonic Acid (Vitamin F)
5.	Proteins (Proteins, Gene)
6.	Triglycerides (Triacylglycerol)
7.	Lithium
8.	Lipoproteins (Lipoprotein)
9.	Phospholipases A2 (Phospholipase A2)
10.	LDL Cholesterol

Related Therapies and Procedures

1.	Injections
2.	Aftercare (After-Treatment)
3.	Splenectomy
4.	Hypophysectomy
5.	Transplants (Transplant)

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 20112 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>